NCT06657222

SEP 11, 2026 · PHASE 1/2 TRIAL

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

ClinicalTrials.gov

First-in-human Phase 1/2 trial of a novel agent in early-stage development; no results posted; designed to establish safety, tolerability, and maximum tolerated dose rather than efficacy.